Analysts who follow Aclaris Therapeutics Inc (ACRS) on average expect it to increase 51.26% over the next twelve months. Those same analysts give the stock an average rating of Buy.
That average rating earns the stock an Analyst Ranking of 14, which means it ranks higher than 14 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating ACRS a Buy today. Find out what this means to you and get the rest of the rankings on ACRS!
Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported.
InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.
What's Happening With Aclaris Therapeutics Inc Stock Today?
Aclaris Therapeutics Inc (ACRS) stock has risen 3.04% while the S&P 500 is lower by -0.11% as of 2:23 PM on Monday, Mar 25. ACRS is up $0.03 from the previous closing price of $1.15 on volume of 374,698 shares. Over the past year the S&P 500 is up 31.45% while ACRS is lower by -85.38%. ACRS lost -$1.27 per share the over the last 12 months.
Click Here to get the full Stock Report for Aclaris Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
